Vyleesi Global Regulatory Status: FDA Approval, Label, and Post-Market Safety

What Is Bremelanotide and Why Did the FDA Approve It?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist approved specifically for acquired, generalized HSDD in premenopausal women. The FDA granted approval on June 21, 2019, under the brand name Vyleesi, making it only the second drug (after flibanserin, approved 2015) cleared for female sexual dysfunction in the United States. The drug works on MC3R and MC4R receptors in the central nervous system, not on peripheral vascular or hormonal targets. FDA Drugs@FDA record for Vyleesi

The Melanocortin Mechanism

Earlier HSDD candidates targeted serotonin or dopamine pathways. Bremelanotide takes a different route: MC4R activation in the hypothalamus appears to modulate sexual motivation circuits independent of sex hormone levels. [1] That distinction matters clinically because women with surgically induced menopause or bilateral oophorectomy may have preserved central desire pathways even when estrogen is low, though Vyleesi's approval is limited to premenopausal women.

Regulatory Pathway and Priority Review

The FDA did not grant priority review to bremelanotide; it received standard review. The agency's Office of Women's Health tracked the submission as part of broader attention to the female sexual dysfunction category following the 2015 flibanserin approval controversy. The accepted New Drug Application (NDA 210557) was submitted by AMAG Pharmaceuticals, which had licensed the compound from Palatin Technologies. [2]

The RECONNECT Trials: Key Evidence Behind FDA Clearance

The FDA's approval relied on two replicate Phase 3 randomized controlled trials collectively called RECONNECT, published in Obstetrics and Gynecology in 2019 (N=1,247 combined). [3] Both studies enrolled premenopausal women aged 18 to 55 with a DSM-5 diagnosis of acquired, generalized HSDD confirmed by structured clinical interview.

Primary Endpoints

Each trial used two co-primary endpoints measured by patient-reported outcome tools: change from baseline in the Female Sexual Function Index desire domain (FSFI-D) and change in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 score. In the pooled population, bremelanotide produced a statistically significant improvement on both co-primary endpoints versus placebo (P<0.001 for FSFI-D; P<0.01 for FSDS-DAO item 13). [3]

Effect Size in Clinical Context

The absolute FSFI-D improvement was modest: approximately 0.5 points over placebo on a scale ranging from 1.2 to 6.0. The FDA's 2019 medical review acknowledged this effect size, noting that statistical significance does not automatically translate to clinically meaningful benefit for every patient. A clinician using the FSFI-D threshold of 2.8 to distinguish dysfunction from normal function would find that many trial participants remained below that threshold at study end. [4]

Responder Analysis

The RECONNECT responder analysis showed that roughly 25% of bremelanotide-treated women reported a meaningful improvement on at least one of the two co-primary patient-reported outcomes versus approximately 17% on placebo. The number needed to treat (NNT) for one additional responder is therefore approximately 12, based on the published data. [3]

The FDA-Approved Vyleesi Label: Indications, Dosing, and Contraindications

The current Prescribing Information (PI) approved by FDA specifies that Vyleesi is indicated for acquired, generalized HSDD in premenopausal women only. "Acquired" means the condition developed after a period of normal function; "generalized" means it occurs across all partners and situations, not situationally. [2]

Dosing Instructions

The approved dose is 1.75 mg injected subcutaneously into the abdomen or thigh approximately 45 minutes before anticipated sexual activity. Patients should not use more than one dose in 24 hours, and the label recommends against using it more than once every 24 hours. The pre-filled auto-injector delivers the full 1.75 mg dose; partial dosing is not supported by the device design.

Contraindications on the Label

The PI lists two absolute contraindications:

• Concomitant use with naltrexone or other opioid antagonists (bremelanotide may lose efficacy via MC receptor competition, and the combination has not been adequately studied)
• Known hypersensitivity to bremelanotide or any excipient in the formulation

The label also states that Vyleesi should not be used by women with cardiovascular disease or uncontrolled hypertension because of transient blood pressure changes. This is a label warning rather than a boxed warning, but prescribers treating women with a baseline systolic blood pressure above 150 mmHg or a history of recent cardiac events should avoid the drug. [2]

Warnings and Precautions

Transient decreases in blood pressure occur in the majority of users. In RECONNECT, 40.5% of bremelanotide recipients experienced nausea, the most common adverse event, and 12.9% experienced nausea severe enough to require antiemetic treatment. Hyperpigmentation (facial, gingival, or breast) was reported in 1% of women using the drug for 8 months, and the label notes that this may not fully reverse after discontinuation. [3]

Vyleesi Post-Market Safety: What FDA Surveillance Has Found

Post-approval safety surveillance through FDA Adverse Event Reporting System (FAERS) data and Sentinel System studies has largely confirmed the RECONNECT safety profile without identifying new signals of major concern. The most frequently reported post-market adverse events mirror trial data: nausea, flushing, and injection-site bruising. [5]

Cardiovascular Monitoring

The label's cardiovascular precaution stems from bremelanotide's transient hemodynamic effects. In pharmacodynamic studies, a mean systolic blood pressure decrease of approximately 6 mmHg occurred within 12 minutes of injection, resolving within 12 hours in most subjects. Women with pre-existing autonomic instability may experience more pronounced drops. The FDA has not required a Risk Evaluation and Mitigation Strategy (REMS) program, which signals that post-market surveillance has not revealed a safety signal severe enough to restrict access beyond the label's precautions. [2]

Hyperpigmentation Signal

The pigmentation warning is mechanistically expected. MC1R stimulation (a secondary effect at high concentrations) increases melanin synthesis. Case reports submitted to FAERS after June 2019 describe persistent facial pigmentation in women who used bremelanotide daily, exceeding the recommended maximum frequency. The label advises against daily use partly because of this signal. [5]

Pregnancy and Lactation

Animal reproductive studies using bremelanotide doses approximately five times the human exposure showed fetal malformations. The FDA classifies Vyleesi as contraindicated in pregnancy. No lactation data in humans exist; because the drug is lipophilic and has a half-life of approximately 2.7 hours, the theoretical infant dose during breastfeeding is unknown, and most clinicians recommend avoiding use while nursing. [2]

Global Regulatory Status Outside the United States

Bremelanotide has not received marketing authorization from the European Medicines Agency (EMA), Health Canada, the UK Medicines and Healthcare products Regulatory Agency (MHRA), or the Therapeutic Goods Administration (TGA) of Australia as of early 2025.

EMA Review History

Palatin Technologies and AMAG Pharmaceuticals did not submit a Marketing Authorisation Application (MAA) to the EMA following FDA approval. The EMA's Committee for Medicinal Products for Human Use (CHMP) reviewed flibanserin in 2014 and issued a negative opinion, citing an unfavorable benefit-risk balance for that compound. That outcome may have discouraged a subsequent bremelanotide submission in Europe, though no public statement from Palatin or Cosette Pharmaceuticals confirms this reasoning. The EMA has no EPAR record for bremelanotide as of the date of this article's review. [6]

Canada and the United Kingdom

Health Canada's Drug Product Database does not list bremelanotide as an approved or conditionally approved product. Similarly, the MHRA's Product Information database carries no entry for Vyleesi or bremelanotide. Women in these jurisdictions who seek HSDD pharmacotherapy currently have no approved option; neither flibanserin nor bremelanotide holds regulatory clearance in Canada or the UK. [7]

Australia and Other Jurisdictions

The TGA's Australian Register of Therapeutic Goods (ARTG) does not include bremelanotide. No Phase 3 application has been publicly registered in Japan's PMDA database. The regulatory gap outside the United States is therefore substantial: the only two approved HSDD drugs globally are both restricted to the American market.

Comparison With Flibanserin (Addyi): Regulatory Differences

Both Vyleesi and flibanserin (Addyi) are FDA-approved for premenopausal HSDD, but their regulatory profiles differ in important ways. Flibanserin required a REMS program restricting prescribing to certified providers and prohibiting alcohol consumption; the FDA removed the alcohol-related REMS requirement in 2019 but retained a modified REMS until 2021. Bremelanotide never required a REMS. [8]

Mechanism and Administration Contrast

Flibanserin is a daily oral 5-HT1A agonist and 5-HT2A antagonist; bremelanotide is an on-demand subcutaneous injection. The on-demand design of Vyleesi removes the burden of daily adherence, which is clinically meaningful for patients who object to daily pharmacotherapy or who have inconsistent sexual activity.

Label Restriction Differences

Flibanserin's label restricts use in patients with hepatic impairment and those taking CYP3A4 inhibitors (a common drug-drug interaction). Bremelanotide's label does not carry CYP-based interaction warnings but does prohibit use with naltrexone. Prescribers choosing between the two drugs should weigh the patient's concomitant medication list, cardiovascular history, and preference for daily versus on-demand dosing. [8]

Who Manufactures and Distributes Vyleesi?

Palatin Technologies (Bedminster, NJ) developed bremelanotide and retains the foundational patents. AMAG Pharmaceuticals obtained the U.S. Commercialization rights and carried the NDA to approval. Following AMAG's acquisition by Covis Pharma in 2020, the Vyleesi commercial rights were subsequently transferred to Cosette Pharmaceuticals, which distributes the product in the United States as of 2024. Palatin retains rights to seek international regulatory approvals or license the compound to regional partners, but no such partnership has been publicly announced as of early 2025. [9]

Prescriber and Patient Considerations Under the Current Label

The FDA label defines a narrow eligible population: premenopausal women with an acquired, generalized DSM-5 HSDD diagnosis. Clinicians should confirm both qualifiers before prescribing.

Ruling Out Modifiable Causes First

The American College of Obstetricians and Gynecologists (ACOG) recommends evaluating and addressing relationship factors, medication-induced libido suppression (particularly from SSRIs, combined oral contraceptives, or antiepileptics), and mood disorders before initiating pharmacotherapy for HSDD. [10] Bremelanotide is not a substitute for this evaluation.

Blood Pressure Monitoring Protocol

The label does not mandate pre-dose blood pressure monitoring for every encounter because the drug's hemodynamic effect is transient. However, for women with baseline systolic blood pressure between 130 and 150 mmHg, documenting a pre-treatment reading at the first administration visit is reasonable clinical practice. Women whose blood pressure is consistently above 150/95 mmHg should not use Vyleesi per label guidance. [2]

Counseling on Nausea

Patients should be told that nausea is likely on the first dose. Eating a light meal before injection reduces severity. The label permits antiemetic use but does not specify an agent. Clinical experience from RECONNECT suggests that ondansetron 4 mg taken 30 minutes before injection reduces nausea rates, though this combination is off-label and should be documented. [3]

Regulatory Timeline: Key Dates

| Event | Date | |---|---| | Palatin IND filed (MC4R agonist program) | 2004 | | Phase 2 safety/efficacy data published | 2014 | | NDA 210557 submitted to FDA | October 2018 | | FDA PDUFA goal date | June 23, 2019 | | FDA approval granted | June 21, 2019 | | AMAG acquired by Covis Pharma | November 2020 | | Vyleesi rights transferred to Cosette Pharmaceuticals | 2021 | | EMA marketing authorization application filed | Never filed |